Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol.

about

Update on the Impact of Omega 3 Fatty Acids on Inflammation, Insulin Resistance and Sarcopenia: A Review.

P2860

Q48260464-B289097D-3DA0-42C2-8DA7-35D65F35477A

P2860

Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol.

Item

http://www.wikidata.org/entity/Q47696256

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Comparing the Impact of Prescr ...... nsity Lipoprotein Cholesterol.

@en

Comparing the Impact of Prescr ...... nsity Lipoprotein Cholesterol.

@nl

type

Item

label

Comparing the Impact of Prescr ...... nsity Lipoprotein Cholesterol.

@en

Comparing the Impact of Prescr ...... nsity Lipoprotein Cholesterol.

@nl

prefLabel

Comparing the Impact of Prescr ...... nsity Lipoprotein Cholesterol.

@en

Comparing the Impact of Prescr ...... nsity Lipoprotein Cholesterol.

@nl

P1476

Comparing the Impact of Prescr ...... ensity Lipoprotein Cholesterol

@en

P2093

Barry J Gales

http://www.w3.org/2001/XMLSchema#string

Riaz Sirajuddin

http://www.w3.org/2001/XMLSchema#string

P2860

Omega-3 polyunsaturated fatty acid supplementation in the prevention of cardiovascular disease

Omega-3 Fatty Acids and Cardiovascular Disease: Are There Benefits?

Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association.

Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).

Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

Retrospective Case Series of Patients with Diabetes or Prediabetes Who Were Switched from Omega-3-Acid Ethyl Esters to Icosapent Ethyl

Omega-3 fatty acid supplementation and cardiovascular disease.

P2888

s40256-017-0253-0

P304

83-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40256-017-0253-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Randall P Sharp

P577

2018-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29080985

http://www.w3.org/2001/XMLSchema#string

P921

lipoprotein

fatty acid

Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol.

about

P2860

P2860

Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921